neoproct peräpuikko
karo pharma ab - fluocortolone pivalate, lidocaine hydrochloride - peräpuikko - fluokortoloni
emla lääkelaastari
aspen pharma trading limited - prilocaine, lidocaine - lääkelaastari - yhdistelmävalmisteet
neoproct yhdistelmäpakkaus peräpuikko ja rektaalivoide, creme
karo pharma ab - fluocortolone pivalate, lidocaine hydrochloride - peräpuikko ja rektaalivoide, creme - fluokortoloni
emla 25 mg/g + 25 mg/g emulsiovoide
paranova oy - prilocaine, lidocaine - emulsiovoide - 25 mg/g + 25 mg/g - yhdistelmävalmisteet
fenylefrin abcur 0.05 mg/ml injektioneste, liuos
abcur ab - phenylephrini hydrochloridum - injektioneste, liuos - 0.05 mg/ml - fenyyliefriini
fenylefrin abcur 0.1 mg/ml injektioneste, liuos
abcur ab - phenylephrini hydrochloridum - injektioneste, liuos - 0.1 mg/ml - fenyyliefriini
fenylefrin sintetica 0.08 mg/ml injektio-/infuusioneste, liuos
sintetica gmbh - phenylephrini hydrochloridum - injektio-/infuusioneste, liuos - 0.08 mg/ml - fenyyliefriini
fenylefrin sintetica 8.2 mg/ml injektioneste, liuos
sintetica gmbh - phenylephrini hydrochloridum - injektioneste, liuos - 8.2 mg/ml - fenyyliefriini
sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.